The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

doi:10.1016/j.jcrc.2022.154053

. 2022 Aug:70:154053.

doi: 10.1016/j.jcrc.2022.154053. Epub 2022 May 12.

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

Harry Zacharias¹, Ritwik Mungara¹, Andrew Peter Wilson², Mervyn Singer¹, Nishkantha Arulkumaran³

Affiliations

¹ Bloomsbury Institute for Intensive Care Medicine, University College London, London, United Kingdom.
² Department of Clinical Microbiology, University College London NHS Foundation Trust, London, United Kingdom.
³ Bloomsbury Institute for Intensive Care Medicine, University College London, London, United Kingdom. Electronic address: nisharulkumaran@doctors.org.uk.

PMID: 35569216
PMCID: PMC9098225
DOI: 10.1016/j.jcrc.2022.154053

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

Harry Zacharias et al. J Crit Care. 2022 Aug.

. 2022 Aug:70:154053.

doi: 10.1016/j.jcrc.2022.154053. Epub 2022 May 12.

Authors

Harry Zacharias¹, Ritwik Mungara¹, Andrew Peter Wilson², Mervyn Singer¹, Nishkantha Arulkumaran³

Affiliations

¹ Bloomsbury Institute for Intensive Care Medicine, University College London, London, United Kingdom.
² Department of Clinical Microbiology, University College London NHS Foundation Trust, London, United Kingdom.
³ Bloomsbury Institute for Intensive Care Medicine, University College London, London, United Kingdom. Electronic address: nisharulkumaran@doctors.org.uk.

PMID: 35569216
PMCID: PMC9098225
DOI: 10.1016/j.jcrc.2022.154053

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no competing interest to declare.

Figures

**Fig. 1**
CRP trajectory of patients receiving dexamethasone alone or dexamethasone with Tocilizumab.

**Fig. 2**
Trajectory of ferritin, B-type natriuretic peptide (BNP), D-dimer, neutrophils, lymphocytes, and neutrophil: lymphocyte ratio (NLR) among patients receiving dexamethasone with Tocilizumab.

See this image and copyright information in PMC

Cited by

Temporal evolution of laboratory characteristics in patients critically ill with COVID‑19 admitted to the intensive care unit (Review).
Kokkoris S, Kanavou A, Kremmydas P, Katsaros D, Karageorgiou S, Gkoufa A, Georgakopoulou VE, Spandidos DA, Giannopoulos C, Kardamitsi M, Routsi C. Kokkoris S, et al. Med Int (Lond). 2023 Sep 14;3(5):52. doi: 10.3892/mi.2023.112. eCollection 2023 Sep-Oct. Med Int (Lond). 2023. PMID: 37810906 Free PMC article. Review.
Anti-inflammatory effects of dexamethasone in COVID-19 patients: Translational population PK/PD modeling and simulation.
Świerczek A, Jusko WJ. Świerczek A, et al. Clin Transl Sci. 2023 Sep;16(9):1667-1679. doi: 10.1111/cts.13577. Epub 2023 Jul 5. Clin Transl Sci. 2023. PMID: 37386717 Free PMC article.
Temporal trends in laboratory parameters in survivors and non‑survivors of critical COVID‑19 illness and the effect of dexamethasone treatment.
Kokkoris S, Kanavou A, Katsaros D, Karageorgiou S, Kremmydas P, Gkoufa A, Ntaidou T, Giannopoulos C, Kardamitsi MA, Dimopoulou G, Theodorou E, Georgakopoulou VE, Spandidos DA, Orfanos S, Kotanidou A, Routsi C. Kokkoris S, et al. Biomed Rep. 2023 Nov 28;20(1):12. doi: 10.3892/br.2023.1700. eCollection 2024 Jan. Biomed Rep. 2023. PMID: 38124763 Free PMC article.
The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A Cross-Sectional Study.
Firouzabadi D, Dehghanian A, DehghanKhalili S, DehghanKhalili S, Hosseini Saadi SM. Firouzabadi D, et al. Health Sci Rep. 2025 Jul 27;8(8):e71036. doi: 10.1002/hsr2.71036. eCollection 2025 Aug. Health Sci Rep. 2025. PMID: 40735253 Free PMC article.
Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
Calderón-Ochoa C, Plamenov-Donchev N, Hernández-Quiñones F, Mendoza-López O, Hinojos-Gallardo LC, Longino-Gómez AJ, Hernádez-Saldaña R, Duque-Rodríguez J, Ishida-Gutiérrez MC. Calderón-Ochoa C, et al. Microbiol Spectr. 2024 Jun 4;12(6):e0249823. doi: 10.1128/spectrum.02498-23. Epub 2024 Apr 30. Microbiol Spectr. 2024. PMID: 38687065 Free PMC article.

References

1. Manson J.J., Crooks C., Naja M., et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594–e602. - PMC - PubMed
1. Group RC Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed
1. Group RC, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed
1. Kooistra E.J., van Berkel M., van Kempen N.F., et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Crit Care. 2021;25:281. - PMC - PubMed
1. Zanella A., Florio G., Antonelli M., et al. Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. Intensive Care Med. 2021:1–14. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Manson J.J., Crooks C., Naja M., et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594–e602. - PMC - PubMed

[2] Manson J.J., Crooks C., Naja M., et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594–e602. - PMC - PubMed

[3] Group RC Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed

[4] Group RC Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed

[5] Group RC, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed

[6] Group RC, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed

[7] Kooistra E.J., van Berkel M., van Kempen N.F., et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Crit Care. 2021;25:281. - PMC - PubMed

[8] Kooistra E.J., van Berkel M., van Kempen N.F., et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Crit Care. 2021;25:281. - PMC - PubMed

[9] Zanella A., Florio G., Antonelli M., et al. Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. Intensive Care Med. 2021:1–14. - PMC - PubMed

[10] Zanella A., Florio G., Antonelli M., et al. Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. Intensive Care Med. 2021:1–14. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

Affiliations

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous